CD8A and neoplasm: Glofitamab cytotoxic activity is demonstrated by the early formation of synapses between lymphoma and T cells, followed by efficient tumor lysis four hours after the encounter, whereas Epcoritamab determines dose-dependent activation of CD4+ and CD8+ T cells in association with perforin release [81].